DOCSLIB.ORG

Reaching More Serving More Health Needs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reaching More Serving More Health Needs 2005 Annual Report Our Credo JOHNSON & 2005 We believe our first responsibility is to the doctors, nurses and patients, to mothers and Reaching more fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality. We must constantly strive to reduce our costs in order to maintain reasonable prices. Customers’ orders must be serviced promptly and accurately. Our suppliers and distributors must have an opportunity to make a fair profit. ANNU people AL REPORT We are responsible to our employees, the men and women who work with us throughout the world. Everyone must be considered as an individual. We must respect their dignity and recognize their merit. They must have a sense of security in their jobs. Compensation must be fair and adequate, and working conditions clean, orderly and safe. We must be mindful of ways to help our employees fulfill their family responsibilities. Employees must feel free to make suggestions and complaints. There must be equal opportunity for employment, development and advancement for those qualified. We must provide competent management, and their actions must be just and ethical. We are responsible to the communities in which we live and work and to the world community as well. We must be good citizens – support good works and charities and bear our fair share Serving more of taxes. We must encourage civic improvements and better health and education. We must maintain in good order the property we are privileged to use, protecting the environment and natural resources. health needs Our final responsibility is to our stockholders. Business must make a sound profit. We must experiment with new ideas. Research must be carried on, innovative programs developed and mistakes paid for. New equipment must be purchased, new facilities provided and new products launched. Reserves must be created to provide for adverse times. When we operate according to these principles, the stockholders should realize a fair return. One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 FINANCIAL HIGHLIGHTS % Change (Dollars in Millions Except Per Share Figures) 2005 2004 2003 2005 2004 Sales to customers $50,514 47,348 41,862 6.7% 13.1 Net earnings 10,411 8,509 7,197 22.4 18.2 Percent return on average shareholders’ equity 29.9 29.0 29.0 — — Diluted net earnings per share $ 3.46 2.84 2.40 21.8% 18.3 Cash dividends paid per share 1.275 1.095 0.925 16.4 18.4 Market price (year-end close) 60.10 63.42 50.62 (5.2) 25.3 Net Sales Diluted Earnings Per Share Dividends Paid Per Share (in billions of dollars) (in dollars) (in dollars) 50 4.0 1.25 40 1.00 3.0 30 0.75 2.0 20 0.50 1.0 10 0.25 0 01 02 03 04 05 0 01 02 03 04 05 0 01 02 03 04 05 ABOUT THE COMPANY TABLE OF CONTENTS Johnson & Johnson achieved $50.5 billion in sales and, Letter to Shareholders ..................................1 through its operating companies, is the world’s most Features ........................................... 5 comprehensive and broadly based manufacturer of health Resources ......................................... 23 care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices Board of Directors ....................................24 and diagnostics markets. The more than 230 Johnson Committees of the Board ...............................25 & Johnson operating companies employ approximately Corporate Officers and Company Group Chairmen ...........26 115,600 men and women in 57 countries and sell products Corporate Governance and Management’s Responsibility ......27 throughout the world. Management’s Discussion and Analysis ...................28 Consolidated Financial Statements .......................39 ON THE COVER Notes to Consolidated Financial Statements ................43 For patients with conditions from coronary artery disease Management’s Report on Internal Control over to bipolar disorder, and consumers looking for advanced Financial Reporting ...................................64 science in skin care, Johnson & Johnson companies’ Report of Independent Registered Public Accounting Firm .....65 products are reaching more people and serving more health Summary of Operations and Statistical Data 1995-2005 .......66 needs around the world. Inside, read the stories of people Reconciliation of Non-GAAP Measures ....................67 whose lives are changed for the better by our products. Principal Global Businesses .............................68 Worldwide Family of Companies .........................73 Corporate and Shareholder Information ...................77 JOHNSON & JOHNSON 2005 ANNUAL REPORT TO OUR SHAREHOLDERS Johnson & Johnson achieved record financial results stories in this year’s annual report relate. Each of our in 2005 and made further progress in preparing businesses plays an important role in this regard. Let me for future growth. Worldwide sales grew to a record provide a few examples. $50.5 billion, a growth rate of nearly 7 percent, The Medical Devices and Diagnostics segment per- with operational growth of 6 percent and a positive formed exceptionally well this past year, with strong currency impact of 1 percent. growth in both revenue and profitability. The segment’s Adjusted net earnings for the year were also at strength was broadly based, with five of the seven record levels, with net income growing at 13.3 percent Medical Devices and Diagnostics franchises growing to $10.5 billion and diluted net earnings per share sales at double-digit rates. The businesses in the segment increasing 12.9 percent to $3.50(1). aspire to a compelling vision: Restoring the joys of life An improvement in mix toward higher margin prod- for patients by establishing standards of care. ucts, productivity increases driven by cost containment As we have pursued this vision over the last decade, efforts, and positive interest and other income all helped our Medical Devices and Diagnostics businesses have drive impressive earnings growth. harnessed the power of science and technology to enhance Our cash flow from operations in 2005 continued to the diagnosis and treatment of disease across a broad be strong at $11.9 billion. In light of this, we increased range of medical and surgical specialties. our quarterly dividend to shareholders for the 43rd consecutive year, this year by nearly 16 percent to $.33. Even with this significant increase, we ended the year with a very strong net cash position of $13.5 billion, providing us the resources to continue important business building investments. A year ago I reported to you our excitement about the prospect of broadening our presence in cardiovascular devices through the acquisition of Guidant Corporation. We extended considerable effort throughout the year to conclude this transaction. Unfortunately, a combination of adverse developments in Guidant’s business and competition for the asset forced the price to a point where we concluded it was no longer in the best interest of our shareholders to pursue this business opportunity. Nonetheless, we remain committed to strengthening our business in this important therapeutic category. Elsewhere, aggressive investment in the future con- tinued unabated. We were successful in advancing our future growth through a series of smaller but nonetheless important acquisitions described later in this letter. And, across the business we invested $6.3 billion in research and development, a $1.1 billion increase, or more than 21 percent, above our 2004 investment. The men and women of Johnson & Johnson are to be recognized for their strong performance this past year. They remain the engine that drives our business forward. They make it possible for Johnson & Johnson to continue to touch people’s lives in a more meaningful way, as the William C. Weldon Chairman, Board of Directors, and Chief Executive Officer TO OUR SHAREHOLDERS PAGE 1 For example, DePuy, the world’s leader in joint Key business building acquisitions in the Medical reconstruction and other important orthopaedic areas, is Devices and Diagnostics segment will continue to be focusing on less invasive and more durable, motion-saving an important source of future growth. Last June, we solutions. iOrthopaedics, DePuy’s computer-assisted acquired Closure Medical Corporation, a global leader navigation platform, affords greater surgical precision and in biomaterial-based medical devices, and in January, improved outcomes in minimally invasive procedures. we added Hand Innovations LLC, bringing leading In interventional cardiology, Cordis’ innovative product technology in the fastest-growing segment of the global solutions are addressing cardiovascular disease, the world’s extremities market. Just last month, we concluded the leading cause of death. CYPHER® Sirolimus-Eluting Stent acquisition of Animas Corporation, an insulin delivery is now the world’s market leader, building on the most company that will operate as part of our successful credible library of clinical evidence on outcomes and LifeScan business and will strengthen our ability to safety to win preference among interventional cardiologists. further advance the treatment of diabetes. Other examples like VICRYL® Plus, the world’s first For our Pharmaceutical segment, 2005 was a challeng- and only antibacterial suture, and Veridex, our diagnostic ing year, with growth well below historical levels. Growth business focused on cancer cell detection at earlier was affected by the impact of generic competition for stages of disease, demonstrate
Load more

Recommended publications
  • Benadryl Allergy Relief Plus Decongestant Capsules
    Distance between cutted line/middel of the spot = 51.6 mm spot = 12 x 2 centered in the margin of 14 mm le f 14 mm GB Benadryl Allergy Relief Plus Decon Caps 12s PIL MAH Update CRD 6738 t margin 23.06.2021 English 402428175_r0 N/A 1 Brochure/Leaet/Insert 145 x 250 mm Capsules are a medicine which are used to blood pressure). 364350C IM_Val-de-Reuil_Upper Normandy_France relieve the symptoms of hay fever and similar ■ If you have glaucoma (increased pressure allergic conditions. The capsules contain in the eye). CTE LITE 364350B Westrock Saint Pierre des Corps pseudoephedrine hydrochloride, which is a ■ If you have an overactive thyroid gland. 845 Oset Printing decongestant that relieves nasal and sinus ■ If you have severe kidney problems. 7996903 PAPER congestion and acrivastine which is an ■ If you are taking, or have taken in the last EMEA_2021_00024796_003 PC-0002778 antihistamine that helps relieve allergy two weeks, drugs for depression known symptoms such as sneezing, runny nose and as Monoamine Oxidase Inhibitors CAPSULES watery eyes. (MAOIs) or Reverse Inhibitors of Acrivastine 8mg & Pseudoephedrine 60mg Monoamine Oxidase 2 Before taking this (RIMAs). ■ This medicine is used to relieve the symptoms ■ If you are taking any cough or of hay fever and similar allergic conditions. cold medicines. PANTONE PANTONE medicine 356 C 287 C ■ This medicine is for use by adults and If any of these apply to you, get advice from children aged 12 - 65 years. This medicine is suitable for most adults under LITHO OFFSET LITHO OFFSET 65 years old and children aged 12 years and a doctor or pharmacist without taking ■ Do not take this medicine: REPRESENTATION: Colours represented with a diagonal line have been modified to aid PDF approval.
    [Show full text]
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • 2Nd Quarter 2015 Earnings Call Presentation
    2nd Quarter 2015 Earnings Call Presentation July 14, 2015 1 Louise Mehrotra Vice President Investor Relations 2 Note on Forward-Looking Statements These presentations contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including global health care reforms; trends toward health
    [Show full text]
  • No. 33981 2 No
    Pretoria, 4 February 2011 Februarle No. 33981 2 No. 33981 GOVERNMENT GAZETTE, 4 FEBRUARY 2011 IMPORTANT NOTICE The Government Printing Works will not be held responsible for faxed documents not received due to errors on the fax machine or faxes received which are unclear or incomplete. Please be advised that an "OK" slip, received from a fax machine, will not be accepted as proof that documents were received by the GPW for printing. If documents are faxed to the GPW it will be the sender's respon­ sibility to phone and confirm that the documents were received in good order. Furthermore the Government Printing Works will also not be held responsible for cancellations and amendments which have not been done on original documents received from clients. CONTENTS INHOUD Bladsy Koerant Page Gazette No. No. No. No. No. No. GENERAL NOTICE ALGEMENEKENNISGEWING Health, Department of Gesondheld, Departement van General Notice A/gemene Kennisgewing 58 Medicines and Related Substances Act 58 Wet op Beheer van Medisyne en (101/1965): Medicines Control Council: Verwante Stowwe (101/1965): Conditions of registration of a medicine Medisynebeheerraad: Voorwaardes vir in terms of the provisions of section die registrasie van 'n medisyne in terme 15 (7) ..................................................... .. 3 33981 van die bepalings van artikel 15 (7) ........ 4 33981 STAATSKOERANT, 4 FEBRUARIE 2011 No. 33981 3 GENERAL NOTICE ALGEMENE KENNISGEWING NOTICE 58 OF 2011 MEDICINES CONTROL COUNCIL CONDITIONS OF REGISTRATION OF A MEDICINE IN TERMS OF THE PROVISIONS OF SECTION 15(7) OF THE MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT 101 OF 1965) 1. The applicant shall ensure that the medicine is manufactured and controlled in terms of the current Good Manufacturing Practices as determined by Council 2.
    [Show full text]
  • IN the UNITED STATES DISTRICT COURT for the DISTRICT of DELAWARE ALZA CORPORATION and JANSSEN PHARMACEUTICALS, INC., Plaintiffs
    Case 1:16-cv-00914-UNA Document 3 Filed 10/07/16 Page 1 of 20 PageID #: 24 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ALZA CORPORATION and ) JANSSEN PHARMACEUTICALS, INC., ) ) Plaintiffs, ) ) v. ) Civil Action No. ____________ ) REDACTED PUBLIC VERSION AMNEAL PHARMACEUTICALS OF ) NEW YORK, LLC and ) AMNEAL PHARMACEUTICALS LLC, ) ) Defendants. ) COMPLAINT In this patent infringement action, Plaintiffs ALZA Corporation ("ALZA") and Janssen Pharmaceuticals, Inc. (collectively "Plaintiffs"), for their complaint against Defendants Amneal Pharmaceuticals of New York, LLC ("Amneal Pharms. NY") and Amneal Pharmaceuticals LLC ("Amneal Pharms. LLC") (collectively, "Amneal"), allege as follows: NATURE OF THE ACTION 1. This is an action for patent infringement under the patent laws of the United States, Title 35, United States Code, in response to, inter alia, the submission by Amneal of Abbreviated New Drug Application ("ANDA") No. 207515, with the U.S. Food and Drug Administration ("FDA") seeking approval to manufacture and sell a generic version of CONCERTA® prior to the expiration of U.S. Patent No. 8,163,798 ("the '798 patent") and U.S. Patent No. 9,144,549 ("the '549 patent"). PARTIES 2. Plaintiff ALZA is a Delaware corporation, having its principal place of business at 700 Eubanks Drive, Vacaville, California 95688. Case 1:16-cv-00914-UNA Document 3 Filed 10/07/16 Page 2 of 20 PageID #: 25 REDACTED PUBLIC VERSION 3. Plaintiff Janssen Pharmaceuticals, Inc. ("Janssen") is a Pennsylvania corporation, having a place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560. 4. On information and belief, Defendant Amneal Pharms. LLC is a limited liability company organized under the laws of the State of Delaware and has a place of business at 400 Crossing Boulevard, Bridgewater, NJ 08807.
    [Show full text]
  • Management Team
    Management Team Bruce C. Cozadd Executive Chairman Bruce Cozadd joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Mr. Cozadd served as a consultant to companies in the biopharmaceutical industry. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. Mr. Cozadd serves on the boards of Cerus Corporation, a biopharmaceutical company; Threshold Pharmaceuticals, a biotechnology company; and The Nueva School and Stanford Hospital and Clinics, both non-profit organizations. Samuel R. Saks, MD Chief Executive Officer Samuel Saks, M.D., joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Dr. Saks was Company Group Chairman of ALZA Corporation and served as a member of the Johnson & Johnson Pharmaceutical Group Operating Committee. From 1992 until 2001, he held various positions with ALZA Corporation, most recently as its Chief Medical Officer and Group Vice President, where he was responsible for clinical and commercial activities. Dr. Saks received a B.S. and an M.D. from the University of Illinois. Dr. Saks serves on the board of Trubion Pharmaceuticals and Cougar Biotechnology. Robert M. Myers President Robert Myers joined Jazz Pharmaceuticals at its inception and was appointed as Jazz Pharmaceuticals’ President in March 2007.
    [Show full text]
  • Notice Under S66 of the Commerce Act 1986 Application by Johnson & Johnson to Acquire the Stock, Assets and Business Of
    PUBLIC COPY Notice under s66 of the Commerce Act 1986 Application by Johnson & Johnson to acquire the stock, assets and business of the Consumer Healthcare division of Pfizer Inc. COMMERCE ACT 1986: BUSINESS ACQUISITION SECTION 66: NOTICE SEEKING CLEARANCE 28 September 2006 The Registrar Business Acquisitions and Authorisations Commerce Commission PO Box 2351 Wellington Pursuant to s66(1) of the Commerce Act 1986 notice is hereby given seeking clearance of a proposed business acquisition. 518689_1.DOC 2 CONTENTS EXECUTIVE SUMMARY PART 1: TRANSACTION DETAILS 1 The business acquisition for which clearance is sought 2 The person giving this notice 3 Confidentiality 4 Participants 5 Interconnected and associated persons 6 Beneficial interests 7 Links between participants 8 Common directorships 9 Business activities of the participants 10 Reasons for the proposed acquisition PART II: IDENTIFICATION OF MARKETS AFFECTED 11 Horizontal aggregation 12 Differentiated product markets 13 Differentiated product markets 14 Vertical integration 15 Other business acquisitions PARTS III, IV AND V: CONSTRAINTS ON MARKET POWERS BY EXISTING AND POTENTIAL COMPETITION AND OTHER POTENTIAL CONSTRAINTS 16 Allergy medication 17 Products for the treatment of worms 18 Thrush treatment CERTIFICATE APPENDICES 1. Heartburn and indigestion remedies (MYLANTA and MOTILIUM) 2. Worm treatments (COMBANTRIN, VERMOX) 3. Cold, flu, nasal decongestant, cough relief and sort throat medications (CODRAL, SINUTAB, SUDAFED, BENADRYL, BRONDECON) 4. Allergy relief products (ACTIFED, SINUTAB, SUDAFED, VISINE, LIVOSTIN) 518689_1.DOC 3 5. Thrush treatments (DIFLUCAN ONE, DAKTARIN, DAKTAGOLD, NIZORAL, SPORANOX) 6. Shampoo (PREGAINE, ROGAINE, NEUTROGENA, JOHNSON’S BABY SHAMPOO) 7. Hand hygiene (PURELL and MICRO SHIELD) 8. Competitor worm treatment products 9. Multinational pharmaceutical businesses: GlaxoSmithKline, Douglas Pharmaceuticals, Alphapharm, Bayer Group 10.
    [Show full text]
  • Page 1 of 27 MD Consult: Diabetes, Diet For: Comprehensive Version
    MD Consult: Diabetes, Diet for: Comprehensive Version: Patient Education Page 1 of 27 Boise Kidney and Hypertension 3525 East Louise Rd Ste 100 Meridian, ID 83642 208-846-8335 Diabetes diet Highlights Lifestyle Changes Essential for People at Risk for Diabetes Lifestyle interventions that include weight loss, dietary changes, and increased physical activity can definitely help prevent or delay the progression to diabetes among at-risk people, suggest several recent studies. Weight loss through diet and exercise is especially important for overweight people with pre-diabetes. Grain Fiber Important for Diabetes Prevention Eating whole-grain, fiber-rich, cereal foods may help reduce the risk of developing type 2 diabetes, indicates a 2007 study in the Archives of Internal Medicine. In the study, people who consumed the most fiber from grains and cereals had a 33% lower risk of developing diabetes than people with the lowest fiber intakes. The study also found an association between high magnesium intake and reduced diabetes risk. Although fruits and vegetables also contain fiber, they did not appear to affect diabetes risk. Low-Fat Dairy Products Incorporating low-fat dairy products (such as yogurt and milk) into a healthy diet may help reduce diabetes risk for women, suggests a study in Diabetes Care. Beware of Internet Dietary Supplement Scams In 2006, the FDA alerted consumers not to be misled by dietary supplements advertised on the Internet as treatments or cures for diabetes. These products have not been scientifically studied or approved. Low-Glycemic Index Diets Food low on the glycemic index -- such as whole grains, fruits, lentils, and soybeans -- can help promote weight loss and heart health.
    [Show full text]
  • ODWB 16 0.Pdf
    PACIFIC UNIVERSITY COLLEGE OF OPTOMETRY 2016 VICTORIA CONFERENCE July 21 to 24, 2016 Delta Victoria Ocean Point Victoria, B.C. CANADA COPE EVENT #111397 Date Speaker Title COPE Verification Thursday, Kathleen Elliott, Pediatrics/Geriatrics – Take 42824 July 21, OD Your Pick (2 hrs) 2 hours 2016 GO Implications of Selected Corneal Jeffrey Urness, 49516 2 hours Conditions on Refractive Surgery OD (2 hrs) AS Therapeutic Environment, Diet and Amber Giannoni, Supplements: What Role Do 40852 1 hour OD They Play in Dry Eye Disease? (1 hr) AS Therapeutic Friday, Amber Giannoni, Dry Eye and Systemic Disease 40851 2 hours July 22 OD (2 hrs) SD Therapeutic 49515 Kathleen Elliott, The ABC’s of Pediatric Eye Care 1 hour OD (1 hr) FV John McGreal, New Ideas in Glaucoma 43612 2 hours OD Management (2 hrs) GL Therapeutic Total hours offered: 10 Total hours earned: Name License # Mailing Address ______ Please retain a copy of this stamped form as verification of hours earned. Please be advised that your individual state board makes the final determination of applicable hours. For more information, contact Pacific University College of Optometry, 2043 College Way . Forest Grove, OR 97116 . 503-352-2202 1 of 193 2 of 193 PACIFIC UNIVERSITY COLLEGE OF OPTOMETRY 2016 VICTORIA CONFERENCE July 21 to 24, 2016 Delta Victoria Ocean Point Victoria, B.C. CANADA COPE EVENT #111397 Date Speaker Title COPE Verification Saturday, John McGreal, The Latest Trends in 43497 2 hours July23 OD Contemporary Medicine (2 hrs) PH Therapeutic Non-Surgical Radiofrequency Kathleen Elliott, 46927 2 hours Periocular Soft Tissue OD Rejuvenation (2 hrs) AS Therapeutic 42998 John McGreal, New Tools for the Tool Box 1 hour OD (1 hr) GO Sunday, Jeffrey Urness, 49517 1 hour Bacterial Corneal Ulcers (1 hr) July 24 OD AS Therapeutic 49514 Kathleen Elliott, Pediatric Case Reports: The 1 hour OD Good, Bad and Ugly (1 hr) FV 43552 Amber Giannoni, Setting Up a Dry Eye Practice 1 hour OD (1 hr) PM Jeffrey Urness, Corneal Transplantation Front 40409 2 hours OD to Back, Side to Side.
    [Show full text]
  • Pursuit Resources Group Ltd First Floor, 4 Freeport Office Village, Century Drive
    Pursuit Resources Group Ltd First Floor, 4 Freeport Office Village, Century Drive, Braintree, Essex, CM77 8YG Telephone E-mail Website 01245 362500 [email protected] www.pursuitgroup.co.uk Candidate: 24870 2000 - 2003 South Bank University – • BA (Hons) Business Administration (2:1) 1998 - 2000 Westcliff High School Education: • A-levels: Biology, General Studies, Psychology 1993 - 1998 St. Bernard’s High School • GCSE’s: 10 A-C subjects, including English, Mathematics and Sciences Notice Period: 2 months Salary £38,000 NB: To give you an enhanced understanding of the candidate we have checked the validity of the information and left the CV in its original format. A media marketing manager with 10+ years’ experience delivering multiple cross-media campaigns for high profile brands. With track record of executing communication strategies and client objectives from conception to completion. Employment History: Media Account Director Nov 16 – present • Manage and coordinate a team to create and develop Nestlé’s Water and Nutrition divisions’ annual marketing strategy • in line with business objectives • Utilise a mix of media channels including above and below the line media (TV, OOH, print, radio, digital, social and • product placements) ensuring relevancy to the target audience • Keep up to date with new media innovations, changing media landscape and trends in the industry • Develop consumer and shopper insights to feed into overall media strategy to present back to senior business leaders • Strategise and implement
    [Show full text]
  • Memorandum JUL 1 6 201D
    Memorandum Subject Date Additional Quota Letters Received by July 15, 2010 (DFN: 630-08.2) JUL 1 6 201D To From Christine A. Sanncrud. Ph.D., Chief "Barbar• J.Illoockholdt, Chief Drug & Chemical Evaluation Section Regul• torn Section Office of Diverison Control Off cL rl Diversion Control On July 15. 2010, this section received your e-mail requesting a review of seventeen (17) quota applications from sixteen (16) registered manufacturers to determine if there arc any pending administrative/legal actions against these applicants and to advise ODE of the findings. ODOR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations. QUOTA APPLICANTS wan NO ADVERSE OR DEROGATORY INFORMATIO N Novartis Consumer I lealth Lincoln (10345) (b)(4);(b)(7)(E) Baxter (10346) Generics Bidco li bda Vintage (10347) Noramco Delaware (10348) Pharmaceuticals International inc. (10349) Pharmedium (10351) Pharmedium (10352) Rhodes (10356) Bio-Pharm (10357) Patheon (10358) Patheon (10359) Watson (10361) B & B (10363) lospira. Inc. NC (10364) Epic Pharma (10366) Mallinckrodt I lobart (10367) Chemtos (10368) Vol. II Page 55 2 Per consultation with the field offices. DEA does not have sufficient grounds to limit, restrict. or deny quota requests from these registrants. Based on this information. ODG suggests that you proceed with the completion of the quota applications. If you have any questions pertaining to this information. please feel free to contact me (b)(6);(b)(7)( or SC C) (b)(6);(b)(7)(C) Vol. II Page 56 Memorandum Subject Date Additional Quota Letters Received as of July 19, 201() (DFN: 630-08.2) stir 2 8 2010,., To Fr ,./"./ Christine A.
    [Show full text]
  • Announcing Listerine® Sensitivity Powered by Crystal Block™ Technology
    O17AC-A1710-29-OCMUL-LTR-PRO 309842 OC-Multi LISS Launch February 2018 Generic - PRO Davis Abbey [email protected] 908-904-5501 Mollie Kasica 10/31/17 1 MK Layout 11/9/17 2 MK Revisions 12/6/17 3 MK Revisions 12/11/17 ƒ MK Release TRIM SIZE: 8.5”w X 11”h BLEED SIZE: 8.75”w X 11.25” ANNOUNCING LISTERINE® SENSITIVITY POWERED BY CRYSTAL BLOCK™ TECHNOLOGY Creates a powerful shield of continuous protection3, † Reaches virtually 100% of the sensitive areas of teethII Dosage: Rinse with 10mL for 60 seconds morning and night, after brushing. Do not swallow Alcohol Free PICK YOUR RINSE Buy any 1 case, get 1 case FREE!* POWERED BY POWERED BY POWERED BY POWERED BY OUR 4 ESSENTIAL ™ RAPID FUSION RAPID FUSION CRYSTAL BLOCK OILS FORMULA TECHNOLOGY ® TECHNOLOGY ® TECHNOLOGY FOR A CLEANER, FRESHER MOUTH LISTERINE® COOL MINT® LISTERINE ZERO® LISTERINE® TOTAL CARE LISTERINE® TOTAL CARE ZERO LISTERINE® SENSITIVITY Antiseptic Mouthwash, 3.2oz Mouthwash, 3.2oz Anticavity Mouthwash, 3.2oz Anticavity Mouthwash, 3.2oz Mouthrinse, 3.2oz [42795] [42830] [30695] [30668] [23595] The only ADA-Accepted Alcohol free. Up to 7X more fl uoride uptake Compared to other fl uoride rinses,||, # Recommend LISTERINE® SENSITIVITY Branded Antiseptic Mouthwash. Less intense taste. than other fl uoride rinses.§, || superior fl uoride uptake. to your patients for long-lasting relief ZERO alcohol option. from the pain of tooth sensitivity.||, † PICK YOUR FLOSS TAKE YOUR BRUSH Buy 2 cases, get 1 case FREE!** Buy 2 cases, get 1 case FREE!** LISTERINE® LISTERINE® LISTERINE® REACH® REACH® TOTAL CARE ULTRACLEAN® COOL MINT™ GENTLE GUM CARE Mint Waxed FLOSS CLEAN 5yd Floss 5yd Floss 5yd Floss 5yd Floss Soft, Compact toothbrush [44026] [44037] [44022] [9864] [9223] Slides as easily as the Removes up to 61% Removes up to 40% Removes up to 52% leading fl oss product… more plaque than the more plaque than the more plaque than the and removes up to 2x leading fl oss product.|| leading fl oss product.|| leading fl oss product.|| more plaque.1, 2 Contact your sales representative to purchase or learn more.
    [Show full text]